Axim Biotechnologies (AXIM) 0.3250 $AXIM AXIM

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Axim Biotechnologies (AXIM) 0.3250 $AXIM

AXIM Biotechnologies, Inc. Increases CanChew Cannabidiol (CBD) Gum Donations By 200%, Beneficiaries Include U.S. Veterans and Legacy Customers
GlobeNewswire - Mon Jul 11, 8:00AM CDT
AXIM Biotechnologies, Inc. (AXIM Biotech), a world leader in hemp cannabinoid research and development, launched the Company's community outreach and legacy customer reward program. AXIM Biotech selected Adopt-A-Soldier Platoon, Inc. as a charitable giving beneficiary that will distribute 3,600 units of award-winning CanChew cannabidiol (CBD) controlled release chewing gum to U.S. Veterans. AXIM also expanded the Company's appreciation program to include legacy customers. In total, AXIM increased product donations by 200% year-over-year and is distributing all products in the month of July.

Medical Marijuana, Inc.'s Investment, AXIM Biotech, Launches World's First Cannabigerol (CBG) Clinical Trials on Psoriasis and Eczema
Marketwired - Tue May 17, 1:06PM CDT
MJNA's Cannabis-Based Drug Development R&D Plans Expand With AXIM Biotech's Clinical Trials on Patent-Pending AX-1602 Including Cannabigerol (CBG)

AXIM Biotech Begins Human Clinical Trials With Cannabigerol (CBG) for Psoriasis and Eczema in Patients
GlobeNewswire - Tue May 17, 8:00AM CDT
AXIM Biotechnologies, Inc. (OTC:AXIM) is pleased to announce to shareholders and the public that the Company is launching human dermatological clinical trials based on AXIM's proprietary, patent-pending topical ointment formulation AX-1602 that includes the "stem cell cannabinoid" cannabigerol (CBG) and other cannabinoids. The two indications for AXIM's AX-1602 in human trials are Psoriasis (PsO) and atopic dermatitis (AD) also known as eczema. Collectively, these conditions will affect nearly two hundred million people worldwide by 2024; combined market estimates are $16 billion by 2022. Conducting the clinical trials is a world-renowned dermatologist and specialist on psoriasis and atopic dermatitis, Dr. Marcus Meinardi, at The Maurits Clinics in The Hague, The Netherlands.

Medical Marijuana, Inc.'s "420" News: Hemp Brands and Investments Capture Attention of Fox Business, CNN Money, Yahoo Beauty and More
Marketwired - Thu Apr 21, 8:02AM CDT
Medical Marijuana, Inc. (OTC PINK: MJNA), the first publicly traded U.S. cannabis stock, is pleased to announce to the Company's shareholders and the public that many of its portfolio brands and investments were featured in "420" mainstream news coverage.

Medical Marijuana, Inc. Announces Its Cannabis Drug Research and Drug Development Pipeline Update
Marketwired - Wed Apr 20, 2:04PM CDT
Medical Marijuana, Inc. (OTC PINK: MJNA) is pleased to announce that the "Company of Firsts" investments are actively fostering cannabis-based drug development and creation of new, innovative medicine delivery methods. These results are intended to expedite the historic reintroduction of cannabis-based medications into U.S. and global healthcare systems.

AXIM Biotech CEO Appointed to American Pain Association Board of Advisors, Addresses American Opioid Abuse Epidemic
GlobeNewswire - Thu Mar 31, 8:00AM CDT
Dr. George E. Anastassov, MD, DDS, MBA and Chief Executive Officer of AXIM Biotechnologies, Inc. (OTC:AXIM) was recently appointed to the American Pain Association (APA)'s Board of Advisors. AXIM Biotech holds more than 15 years of cannabis-based research and development knowledge of non-addictive pain alleviating alternatives to highly addictive opioid-based medications. The APA Board is appealing to the Surgeon General of the United States to actively address the nation's largest epidemic: prescription opioid pain medication abuse.

AXIM Biotechnologies Expands Executive Team and Advisory Board With Finance and Pro Sports Leaders: Seth Yakatan and Marvin Washington
GlobeNewswire - Thu Jan 28, 7:59AM CST
AXIM Biotechnologies (OTC:AXIM) is proud to announce the following finance and community outreach-focused additions to the Company's advisory board:

UPDATE - AXIM Featured by Reuters: Biotech Receives Cannabis Strains at "Discount for Gum to Treat Multiple Sclerosis"
GlobeNewswire - Thu Jan 28, 7:55AM CST
A groundbreaking story by Reuters global news agency profiled AXIM Biotechnologies, Inc. (OTC:AXIM) and the company's upcoming clinical trials on the world's first patented controlled-release cannabinoid chewing gum MedChew Rx(TM).

AXIM Biotechnologies Featured in Marijuana Documentary "Cannabis is Medicine"
GlobeNewswire - Wed Jan 13, 8:15AM CST
AXIM Biotechnologies, Inc. (OTC:AXIM) is pleased to announce that the Company's efforts on clinical development of a patented cannabinoid-based medical chewing gum will be featured in a documentary to be released in the first quarter of 2016. The documentary Cannabis is Medicine is produced by Jordan Guzzardo, Emmy award-winning documentarian and photojournalist.

Medical Marijuana, Inc. Investment - AXIM Biotech - Featured by Reuters; Cannabis "Gum to Treat Multiple Sclerosis" Pain and Spasticity
GlobeNewswire - Wed Jan 06, 8:00AM CST
Medical Marijuana, Inc. (OTC Pink:MJNA) is proud to announce to the public and its shareholders that its portfolio investment, AXIM Biotechnologies, Inc. (OTC:AXIM), was recently featured in a Health article by Reuters global news agency. The article profiles AXIM's role in developing the world's first patented cannabinoid release chewing gum (i.e. THC, CBD, CBG, etc.) - MedChew Rx(TM) - for pain and spasticity in multiple sclerosis (MS).

AXIM Featured by Reuters: Biotech Receives Cannabis Strains at "Discount for Gum to Treat Multiple Sclerosis"
GlobeNewswire - Tue Jan 05, 12:39PM CST
A groundbreaking story by Reuters global news agency profiled AXIM Biotechnologies, Inc. (OTC:AXIM) and the company's upcoming clinical trials on the world's first patented controlled-release cannabinoid chewing gum MedChew Rx(TM).

AXIM Biotech Explains Cannabis Chewing Gum Clinical Trials for Pain and Spasticity With MS, Plans to Enter General Pain Market
GlobeNewswire - Thu Aug 20, 8:37AM CDT
News of clinical trials on a new pharmaceutical cannabis chewing gum treatment option for pain and spasticity in Multiple Sclerosis (MS) patients by AXIM Biotechnologies, Inc. (OTC:AXIM) is spreading. Initial reports include: Multiple Sclerosis News Today, Marketwatch, Yahoo! Finance, Wall Street Journal, CNN Money, Marijuana Stocks Report, Culture Magazine, and Pharmacy Choice.

MJNA's Investment Company AXIM Biotech Announces Clinical Trial Launch of MedChew RX for Treatment of Pain and Spasticity in Multiple Sclerosis and Development of Pharmaceutical Cannabis Chewing Gum
GlobeNewswire - Thu Aug 13, 8:00AM CDT
Medical Marijuana, Inc. (OTC Pink:MJNA) is an agricultural hemp industry innovator that sources, evaluates, invests in and acquires value-adding companies with a focus on industrial hemp. The Company is pleased to announce that one of its investments - AXIM Biotechnologies, Inc. (OTC:AXIM) - is conducting clinical trials of its patented pharmaceutical chewing gum MedChew(TM) RX in Europe. The cannabinoid controlled-release chewing gum is the first of its kind and is being developed for patients suffering from pain and/or spasticity associated with multiple sclerosis (MS).

AXIM Biotech Announces Launch of Clinical Trials on MedChew RX(TM) and Development of Pharmaceutical-Grade Cannabis Chewing Gum
GlobeNewswire - Tue Aug 11, 8:00AM CDT
AXIM Biotechnologies, Inc. (OTC:AXIM) is a unique biotechnology corporation with a focus on global research, development and production of pharmaceutical, nutraceutical, food and cosmetic products - all derived from industrial hemp. AXIM Biotech is pleased to announce that the Company has started clinical development of its leading patented pharmaceutical chewing gum, MedChew RX(TM), for registration as a drug for patients suffering from pain and/or spasticity associated with multiple sclerosis (MS).

AXIM Biotechnologies Clarifies Relationship With Medical Marijuana, Inc. and CanChew Biotechnologies, LLC
GlobeNewswire - Fri Jul 31, 7:00PM CDT
A statement from AXIM Biotechnologies (OTC:AXIM), an innovative biotechnology company:

Medical Marijuana, Inc.'s CanChew -- Patented Cannabis Gum -- Featured in ABC, NBC, CBS, Yahoo! News and More From Chicago Cannabis Convention
GlobeNewswire - Thu Jul 30, 8:00AM CDT
As Illinois implements the state's accessibility to medical cannabis, many patients, healthcare and legal professionals exchanged knowledge and resources at the 2 annual My Compassion Chicago Cannabis Conference at Navy Pier July 23-25. There, CanChew, the first patented cannabis chewing gum, was sampled by show goers. CanChew also captured the attention of both mainstream and industry news reporters in features including: ABC, NBC, CBS, Yahoo News, Telemundo, WGN, Marijuana Investor News and more.

AXIM Biotech Presents Patented Cannabinoid Delivery Methods at My Compassion's Chicago Cannabis Conference
GlobeNewswire - Wed Jul 29, 7:59AM CDT
AXIM Biotechnologies, Inc. (OTC:AXIM) CEO George E. Anastassov, MD, DDS, MBA, proudly shared the Company's cannabinoid delivery methods - including the world's first patented cannabinoid release chewing gum - at the My Compassion Chicago Cannabis Conference. The three-day conference took place at Chicago's Navy Pier and focused on medical cannabis and hemp education with patients, industry professionals and the public.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 312

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading
3TREES Tests a Bigger Asia-Pacific Growth Blueprint

Updated Category News Views 350

A bucket of paint rarely sounds strategic until it sits inside a regional supply chain. That is the useful part of 3TREES chairman and president Hong Jie's message from the Asia-Pacific Economic Cooperation CEO Summit in Shenzhen on November 17-18, 2026: coatings are not merely a commodity if the supplier can bring materials, energy savings, technical know-how and...

Continue Reading
Ajman Memory Gives Heritage a Durable Digital Backbone

Updated Category News Views 303

Archives usually get applause only after somebody realizes a piece of history has vanished. Ajman is trying to skip that miserable part. During the Ajman Media Forum 2026, held November 18 and 19 at the Emirates Hospitality Centre, the emirate launched Ajman Memory, a project built to collect, document and preserve photographs, papers and video recording its development....

Continue Reading
Human Frontier Mission Puts AI Research on Display

Updated Category News Views 330

A laboratory notebook is about to become the real product in this AI experiment. Human Frontier Mission, or HFM, says it will launch globally on Nov. 24, opening a research program where domain specialists frame scientific and engineering problems while autonomous AI agents develop and test possible answers. The unusual bit is not merely handing models difficult work. It...

Continue Reading
Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 638

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading
Fluence Investors Face a November 27 Litigation Clock

Updated Category News Views 342

Six calendar squares are all that separate eligible Fluence investors from the November 27, 2026 lead-plaintiff deadline. That is not much time to locate trade confirmations, calculate losses, and decide whether taking a larger role in a securities case makes sense. The lawsuit is not a verdict, and anybody pretending otherwise is selling smoke. But the underlying...

Continue Reading
D-Wave Investors Face a December 15 Lead Plaintiff Clock

Updated Category News Views 479

August Put the Story Under a Harsh Light Two ugly August trading sessions are doing a lot of work in the case now confronting D-Wave Quantum. The company sits in a field that attracts big dreams, big headlines, and, frankly, plenty of investor imagination. But imagination does not cushion a portfolio when expectations crack. The lawsuits concern people who bought or...

Continue Reading
PettiChat’s Digital Pet Twin Has Real Consumer Pull

Updated Category News Views 389

A Collar Gadget Is Chasing the Empty-House Problem Leave a dog or cat alone for a few hours and plenty of owners turn into amateur detectives. Did the cat eat? Has the dog been pacing? Why was that one weird noise caught on the home camera? Seattle startup PettiChat is trying to turn that itch into a product category with PettiLive!, a screen-based version of a pet that...

Continue Reading
FASTEN Data Offers an Early Look at Ladera Closure

Updated Category News Views 122

Femoral access may be the unglamorous part of a valve procedure, but it is where an otherwise tidy case can turn ugly in a hurry. That makes Ladera Medical's full FASTEN data worth a careful look. The company reported results in 55 patients undergoing transfemoral TAVR/TAVI, and the numbers presented at London Valves 2026 suggest its large-bore closure system may address...

Continue Reading
DataBeyond Puts AI Sorting Before a Waste Mountain

Updated Category News Views 182

Trash is a lousy place to look for technological glamour, which is precisely why DataBeyond's COP31 appearance deserves a sober look. On November 19 in Antalya, Türkiye, the Hangzhou-based equipment provider used a China Pavilion event to lay out its case for AI, optical sensing and robots in resource recovery. That is not a magic-green headline. It is a practical...

Continue Reading

Top 5 Most Recently Viewed Articles

HALiXPEDITE Revolutionizes Biologics Therapy Development Process

Updated Category News Views 147

HALiXPEDITE: Transforming the Future of Biologics Development HALIX, a prominent global healthcare Contract Development and Manufacturing Organization (CDMO), recently unveiled its innovative platform, HALiXPEDITE, at a notable conference. This platform is specifically designed to expedite the development of biologics therapies, focusing on a streamlined approach to...

Continue Reading
Day One Biopharmaceuticals to Share Q3 2025 Insights

Updated Category News Views 170

Day One Biopharmaceuticals to Present Q3 2025 Financial Results In a busy season for the biopharmaceutical industry, Day One Biopharmaceuticals (Nasdaq: DAWN) has announced it will host a live conference call and webcast aimed at reporting its financial results and outlining corporate progress for the third quarter of 2025. Conference Call Details The event is scheduled...

Continue Reading
Leica Biosystems Promotes DICOM Standards for Digital Pathology

Updated Category News Views 114

Leica Biosystems Promotes DICOM Standards for Digital Pathology Leica Biosystems, a prominent figure in anatomic pathology, has recently made waves in the medical field with a bold new initiative. By announcing the non-enforcement of their Digital Pathology DICOM (Digital Imaging and Communications in Medicine) patent portfolio, they aim to boost the implementation of...

Continue Reading
LYNPARZA: A Breakthrough in Early Breast Cancer Treatments

Updated Category News Views 288

Significant Survival Benefits with LYNPARZA in Breast Cancer Recent findings from the OlympiA Phase III trial bring exciting news for patients battling early breast cancer. AstraZeneca and Merck & Co., Inc.'s LYNPARZA (olaparib) has showcased profound improvements in survival rates among patients with germline BRCA-mutated HER2-negative high-risk early breast cancer. This...

Continue Reading
EuroDry Limited's Stock Experiences Volatility Amid Challenges

Updated Category News Views 229

EuroDry Limited Faces Stock Turmoil EuroDry Ltd. (NASDAQ: EDRY), a leading provider in drybulk shipping, has recently encountered a tumultuous phase, with its stock reaching a noteworthy low at $14.1. This decline marks a significant reflection on the year's challenges the company has faced, indicated by a -14.71% change over the past year. Market Conditions and...

Continue Reading